Mental Health Client-Level Data (MH-CLD) 2022: Data on Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies annual report presents the total number of clients receiving mental health treatment services in 2022 by demographics, National Outcome Measures (NOMs), and the top five mental health diagnoses for children (ages 0-17) and adults (ages 18 and older) by geographic distribution, and a summary of client characteristics for the 2018-2022 reporting periods.
Dashboard: Filter Bricks
Main page content
This issue brief provides information for State Mental Health Authorities (SMHA) about strategies for promoting person-centered planning (PCP) to enhance the quality of behavioral health services and the valued recovery outcomes of those that use them.
This report looks at state and federal laws and policies that encourage braided funding to provide substance use disorder services, best practices for braiding funds, and pathways to sustainability for substance use disorder programs.
This brief report presents self-reports of recovery among adults aged 18 and older in the United States who thought they ever had a problem with their use of drugs or alcohol and/or mental health. These findings provide a clearer characterization of the factors associated with recovery among adults and how future efforts can foster a whole-health approach to sustain recovery from mental health and substance use conditions.
Drug Abuse Warning Network (DAWN): Drug-Related ED Visits Involving Suicide Attempts Short Report presents national estimates and characteristics of drug-related ED visits involving suicide attempts and the top substance involved in suicide attempts.
This report will include data on the cost of CSC programs; how it is financed; case studies of cost reimbursement methodologies; funding options; trends in costs and financing for CSCs; data evaluation of Medicaid and private insurance coverage and barriers.
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.
Displaying 1 - 10 out of 84